AbbVie says FDA approves Skyrizi for children 6 and older with plaque psoriasis, psoriatic arthritis
The approval adds a new 55 mg pre-filled syringe for patients weighing less than 40 kg and makes Skyrizi the first IL-23 inhibitor cleared in the U.S. for those pediatric groups.